参考文献/References:
[1] Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus.
Lancet Oncol, 2011, 12(5): 489-495.
[2] 黄 琦,江志伟,黎介寿 . 癌性恶病质的药物治疗与营养支持 .肠外与肠内营养,2004,11(6):377-379.
[3] 吴国豪 . 肿瘤恶病质机制及防治对策 . 肠外与肠内营养,2000,7(3):182-186.
[4] Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer, 2002, 2(11): 862-871.
[5] Fearon KC, Moses AG. Cancer cachexia. Int J Cardiol, 2002, 85(1): 73-81.
[6] Argiles JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer, 2014, 14(11):
754-762.
[7] Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review.
J Pain Symptom Manage, 2007, 34(1): 94-104.
[8] Dalal S. Lipid metabolism in cancer cachexia. Ann Palliat Med,2019, 8(1): 13-23.
[9] Feron KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab, 2012, 16(2):
153-166.
[10] Willemsen ACH, Degens JHRJ , Baijens LWJ, et al. Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in
Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Front Nutr, 2020, 7:600612.
[11] Kays JK, Shahda S, Stanley M, et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX
therapy for pancreatic cancer. J Cachexia Sarcopenia Muscle,2018. 9(4): 673-684.
[12] Han J, Tang M, Lu C, et al. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients
with cachexia. Clin Nutr, 2021,40(9):5156-5161.
[13] Batista ML, Peres SB, McDonald ME, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear
transcription factors. Cytokine, 2012, 57(1): 9-16.
[14] Batista ML, Neves RX, Peres SB, et al. Heterogeneous timedependent response of adipose tissue during the development of
cancer cachexia. J Endocrinol, 2012, 215(3): 363-373.
[15] Bing C, Russell S, Becket E, et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue
in tumour-bearing mice. Br J Cancer, 2006, 95(8): 1028-1037.
[16] Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia.
Semin Cell Dev Biol, 2016, 54: 68-81.
[17] Shi H, Cave B, Inouye K, et al. Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not
systemic insulin resistance. Diabetes, 2006, 55(3): 699-707.
[18] Patel HJ, Patel BM. TNF-alpha and cancer cachexia: Molecular insights and clinical implications. Life Sci, 2017, 170: 56-63.
[19] Hauner H, Petruschke T, Russ M, et al. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid
metabolism of newly-differentiated human fat cells in cell culture. Diabetologia, 1995, 38(7): 764-771.
[20] Rinninger F, Kaiser T, Mann WA, et al. Lipoprotein lipase mediates an increase in the selective uptake of high density
lipoprotein-associated cholesteryl esters by hepatic cells in culture. J Lipid Res, 1998, 39(7): 1335-1348.
[21] Kuemmerle NB, Rysman E, Lombardo PS, et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol
Cancer Ther, 2011, 10(3): 427-436.
[22] Thompson MP, Koons JE, Tan ET, et al. Modified lipoprotein lipase activities, rates of lipogenesis, and lipolysis as factors
leading to lipid depletion in C57BL mice bearing the preputial gland tumor, ESR-586. Cancer Res, 1981, 41(8): 3228-3232.
[23] Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire
fatty acids. Prog Lipid Res, 2013, 52(4): 585-589.
[24] Kaderi MA, Kanduri M, Buhl AM,, et al. LPL is the strongest prognostic factor in a comparative analysis of RNA-based
markers in early chronic lymphocytic leukemia. Haematologica,2011,96(8):1153-1160.
[25] Fried SK, Zechner R. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis,
and activity. J Lipid Res, 1989, 30(12): 1917-1223.
[26] Arner P, Langin D. Lipolysis in lipid turnover, cancer cachexia,and obesity-induced insulin resistance. Trends Endocrinol Metab,
2014, 25(5): 255-262.
[27] Zechner R, Zimmermann R, Eichmann TO, et al. FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling. Cell
Metab, 2012, 15(3): 279-291.
[28] Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science, 2011, 333
(6039): 233-238.
[29] Tsoli M, Schweiger M, Vanniasinghe AS, et al. Depletion of white adipose tissue in cancer cachexia syndrome is associated
with inflammatory signaling and disrupted circadian regulation.PLoS One, 2014, 9(3): e92966.
[30] Lass A, Zimmermann R, Oberer M, et al. Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of
cellular fat stores. Prog Lipid Res, 2011, 50(1): 14-27.
[31] Zuijdgeest-van Leeuwen SD, van den Berg JW, Wattimena JL, et al. Lipolysis and lipid oxidation in weight-losing cancer patients
and healthy subjects. Metabolism, 2000, 49(7): 931-936.
[32] Han J, Meng Q, Shen L, et al. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and
browning. Lipids Health Dis, 2018, 17(1): 14.
[33] Silvério R, Lira FS, Oyama LM, et al. Lipases and lipid dropletassociated protein expression in subcutaneous white adipose
tissue of cachectic patients with cancer. Lipids Health Dis, 2017,16(1): 159.
[34] Granneman JG, Moore HP, Krishnamoorthy R, et al. Perilipin controls lipolysis by regulating the interactions of AB-hydrolase
containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). J Biol Chem, 2009, 284:34538–34544.
[35] Granneman JG, Moore HP, Granneman RL, et al. Analysis of lipolytic protein trafficking and interactions in adipocytes. J Biol
Chem, 2007,282:5726–5235.
[36] Subramanian V, Rothenberg A, Gomez C, et al. Perilipin A mediates the reversible binding of CGI-58 to lipid droplets in
3T3-L1 adipocytes. J Biol Chem, 2004, 279:42062–42071.
[37] Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev, 2009,89(2): 381-410.
[38] Cabassi A, Tedeschi S. Zinc-alpha2-glycoprotein as a marker of fat catabolism in humans. Curr Opin Clin Nutr Metab Care, 2013,16(3): 267-271.
[39] Peirce V, Carobbio S, Vidal-Puig A. The different shades of fat,Nature, 2014, 510 (7503): 76-83.
[40] Wu J, Bostr?m P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human, Cell,
2012, 150: 366-376.
[41] Nedergaard J, Cannon B. The browning of white adipose tissue:some burning issues, Cell metabolism, 2014,20:396-407.
·55·肠外与肠内营养 2022年 1月 第 29卷 第 1期 Parenteral & Enteral Nutrition, Vol.29, No.1, January, 2022
[42] Seale P, Conroe HM, Estall J, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in
mice, The Journal of clinical investigation, 2011,121 : 96-105.
[43] Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans, The New
England journal of medicine, 2009,360 :1509-1517.
[44] Mulya A, Kirwan JP. Brown and Beige Adipose Tissue: Therapy for Obesity and Its Comorbidities? Endocrinology and
metabolism clinics of North America, 2016, 45:605-621.
[45] Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia,
Nature, 2014,513:100-104.
[46] Holmes D. Metabolism: WAT browning--key feature of cancerassociated cachexia. Nat Rev Endocrinol. 2014, 10(10):578.
[47] Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancerassociated cachexia. Cell Metab, 2014, 20(3):433-447.
[48] Jorge AS, Jorge GC, Paraíso AF, et al. Brown and White Adipose Tissue Expression of IL6, UCP1 and SIRT1 are Associated with
Alterations in Clinical, Metabolic and Anthropometric Parameters in Obese Humans. Exp Clin Endocrinol Diabetes, 2017, 125(3):
163-170.
[49] Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab
Care, 2005, 8(3): 265-269.
[50] Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis, 2016, 5(2): e200.
[51] Biswas AK, Acharyya S. Understanding cachexia in the context of metastatic progression. Nat Rev Cancer, 2020, 20(5):274-284.
[52] Han J, Lu C, Meng Q, et al. Plasma concentration of interleukin-6 was upregulated in cancer cachexia patients and was positively correlated with plasma free fatty acid in female patients. Nutr Metab (Lond). 2019, 16:80.
[53] Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets, 2013, 17(11): 1303-1328.
[54] Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care, 2014, 8
(4): 321-327.
[55] Dolan RD, Laird BJA, Klepstad P, et al. An exploratory study examining the relationship between performance status and
systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine (Baltimore), 2019, 98(37): e17019.
[56] Scott HR, McMillan DC, Crilly A, et al. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer.
British Journal of Cancer, 1996, 73(12): 1560-1562.
[57] Iwase S, Murakami T, Saito Y, et al. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia
in cancer patients. Eur Cytokine Netw, 2004, 15(4): 312-316.
[58] Yeh KY, Li YY, Hsieh LL, et al. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival
of patients with colorectal cancer. Jpn J Clin Oncol, 2010, 40(6):
580-587.
[59] Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments . J Cachexia
Sarcopenia Muscle, 2013, 4(2): 95-109.
[60] Penet MF, Bhujwalla ZM. Cancer cachexia, recent advances, and future directions . Cancer J, 2015, 21(2): 117-122.
[61] Graziano F, Ruzzo A, Santini D, et al. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene
polymorphisms in patients with advanced gastric cancer . J Clin Oncol, 2005, 23(10): 2339-2345.
[62] Inácio Pinto N, Carnier J, Oyama LM, et al. Cancer as a Proinflammatory Environment: Metastasis and Cachexia .
Mediators Inflamm, 2015, 2015: 791060.
[63] Chang H, Kwon O, Shin MS, et al. Role of Angptl4/Fiaf in exercise-induced skeletal muscle AMPK activation . J Appl
Physiol (1985), 2018, 125(3): 715-722.
[64] Neto NIP, Boldarine VT, Hachul ACL, et al. Association between ANGPTL-4 and the proinflammatory process in cancer cachexia
patients. Oncotarget, 2019, 10(60): 6444-6455.
[65] Yang YH, Wang Y, Lam KS, et al. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the
carboxyl terminus of angiopoietin-like protein 4 . Arterioscler Thromb Vasc Biol, 2008, 28(5): 835-840.
[66] Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor
cell motility and invasiveness . Proc Natl Acad Sci USA, 2006,103(49): 18721-18726.
[67] Sadeghi M, Keshavarz-Fathi M, Baracos V, et al. Cancer cachexia: Diagnosis, assessment, and treatment. Crit Rev Oncol
Hematol, 2018, 127:91-104.
[68] Molfino A, Amabile MI, Giorgi A, et al. Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials. Expert Opin Investig Drugs, 2019, 28(8):733-740.
[69] Dev R, Wong A, Hui D, et al. The Evolving Approach to Management of Cancer Cachexia. Oncology (Williston Park).
2017, 31(1):23-32.
[70] Meng Q, Tan S, Jiang Y, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk
after surgery for gastric cancer: A randomized clinical trial. Clin Nutr, 2021, 40(1):40-46.
[71] Lu S, Li Y, Shen Q, et al. Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia. J
Cachexia Sarcopenia Muscle. 2021, 12(3):779-795.
[72] Chen X, Wu Y, Yang T, et al. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. J Cachexia Sarcopenia Muscle, 2016, 7(2):225-232.